Submitted Successfully!
Thank you for your contribution! You can also upload a video entry related to this topic through the link below: https://encyclopedia.pub/user/video_add?id=20701
Check Note
2000/2000
Ver. Summary Created by Modification Content Size Created at Operation
1 + 1900 word(s) 1900 2022-03-09 06:52:10 |
2 format correction Meta information modification 1900 2022-03-18 02:46:22 |
Congenital Zika Syndrome
Edit
Upload a video

Zika virus (ZIKV) is a single-stranded ribonucleic acid (RNA) flavivirus transmitted by arthropod vectors, in particular, Aedes aegypti (or yellow fever mosquito, also responsible for the transmission of Dengue and Chikungunya) and Aedes albopictus (or Asian tiger mosquito, also responsible for the transmission of Chikungunya and West Nile virus). The virus replicates in the insect’s epithelial cells and, eventually, in the salivary glands. 

Zika virus pregnancy microcephaly prenatal diagnosis neuroimaging long-term outcomes single nucleotide polymorphisms (SNPs)
Information
Subjects: Allergy
Contributor :
View Times: 104
Revisions: 2 times (View History)
Update Date: 21 Mar 2022
Table of Contents

    1. Introduction

    ZIKV is a single-stranded ribonucleic acid (RNA) flavivirus transmitted by arthropod vectors, in particular, Aedes aegypti (or yellow fever mosquito, also responsible for the transmission of Dengue and Chikungunya) and Aedes albopictus (or Asian tiger mosquito, also responsible for the transmission of Chikungunya and West Nile virus). The virus replicates in the insect’s epithelial cells and, eventually, in the salivary glands. ZIKV infection used to be considered a tropical disease, but global interest has increased since 2015 due to an epidemic of neonatal microcephaly in Brazil. The virus has been found capable of crossing the placenta in all gestational periods, but mainly in the first trimester. The infection has also been shown to be transmissible sexually and through transfusions [1]. Another important aspect is that the vector Aedes aegypti varies seasonally in the United States [2]. No treatment or vaccine as yet exists for ZIKV. Symptomatic infection is characterized by low-grade fever, maculopapular rash, arthralgia, and conjunctivitis (some cases of Guillain-Barré syndrome have also been reported in adults); although the symptoms may last for about 5–7 days, 80% of cases are asymptomatic, which greatly complicates the diagnosis in pregnancy. Congenital ZIKV infection may accurately be viewed as a newcomer of the TORCH complex, an acronym that stands for toxoplasmosis, others (syphilis, varicella-zoster, parvovirus B19), rubella, cytomegalovirus (CMV), herpesvirus (HSV), given the characteristics it shares with such well-known pregnancy diseases with mild symptoms in the mother, vertical transmission, severe anomalies in the new-born and maternal therapy, which often fails to improve the prognosis [3]. Although it is a relatively new disease, many national and international associations have already drawn up guidelines for ZIKV infection in pregnancy [4], stressing the need for wide-ranging interventions via family-based support programmes aimed at addressing the special needs of children with CZS neurodevelopmental disability in low- and middle-income countries [5][6], as well as the socioeconomic struggles and psychological impact burdening their families [7][8]. All such issues have been further worsened by the COVID-19 pandemic. As the SARS-CoV-2 curve of infections grew at the height of the pandemic, so did the strain caused by ZIKV on public health facilities in countries where CZS already posed a threat long before the current pandemic [9][10]. The two diseases do bear similarities in terms of clinical manifestations, particularly in the early stages; such an ambiguity can cause delays in diagnosis and treatment interventions, thus, fostering the spread of infection and raising the risk of adverse clinical outcomes. Delays in diagnosis and treatment due to symptoms similar to COVID-19 and other infectious diseases such as Dengue and typhoid fever have also been reported. In India and Pakistan [11][12], the similarity between COVID-19 symptoms and other diseases has reportedly caused misdiagnosis and possible underreporting.

    2. Pathogenesis

    ZIKV has a unique ability among flaviviruses to cross the placental barrier (for example, Dengue virus does not have the same capacity) [13]. Hypothesized transmission routes are: direct infection of the syncytiotrophoblast layer, passage through ruptures in the syncytiotrophoblast layer, crossing of the syncytiotrophoblast layer through non-replicative routes (for example antibody-mediated transcytosis), infection of extravillous trophoblast or other more permissive placental cells (for example, cell of the maternal microvasculature and/or decidua), transmission to the fetus and/or villous core through maternal cells (most probably of immune origin), ascending vaginal infection [14]. The placental damage caused by the virus is related to local inflammation and/or metabolic alterations with mitochondrial dysfunction and loss of function of membrane lipids; the latter seem to rearrange themselves and to support viral replication [15]. ZIKV can reportedly upregulate the innate immune response of the decidua (an aspect in common with CMV), while some findings also show that the mechanism of damage of the maternal-fetal interface is not inflammation-mediated, but only related to the upregulation of apoptosis in placental cells [16]. Once the ZIKV has reached the fetal bloodstream, given its marked neurotropism, the damage is mainly neuronal. The pathogenetic mechanism has been hypothesized to be inflammatory initially for toxoplasma, CMV and rubella, the three most studied etiological agents that cause microcephaly by congenital infection [17]. Studies have also shown how the marked neurotropism of the virus may depend on a specific receptor on neural progenitor cells. In murine animal models, ZIKV infection has, at times, exhibited interference with cell cycle progression; neuronal cells may, therefore, become unable to migrate in the genesis of the telencephalon; for this reason, neurospheres and brain organoids cannot develop [18]. Reportedly, 1 to 42% of embryos or fetuses that are exposed to ZIKV infection in utero develop congenital Zika syndrome (CZS) [19]. Still, it is worth noting that the discovery of the viral teratogenic potential associated with ZIKV is relatively recent; hence, the degree of susceptibility and the mechanisms involved in the adverse effects on embryos and developing fetuses exposed to it are still not fully understood [20]. It is, therefore, essential to evaluate how susceptibility to ZIKV teratogenesis can be affected by environmental and genetic factors (e.g., the inflammatory process of response to ZIKV as risk or protective factors for CZS and the involvement of genetic variants in such dynamics).

    3. Genetic Risk Factors

    Technological advances are increasingly contributing to clarifying the key factors that affect and shape the dynamics of emerging infections, including ZIKV. Techniques such as genome-wide association studies [21], high-throughput sequencing [22] and screening based on clustered regularly interspaced short palindromic repeat (CRISPR) [23][24] has made it possible to identify human single nucleotide polymorphisms (SNPs), which may substantially affect the outcome of infectious diseases [25]. Polymorphisms in NOS2 and TNF genes have been reported to play a role in the development of CZS, with a higher risk in the first trimester, and of severe microcephaly. Specifically, genes closely linked to immune and inflammatory response, such as VEGFA, PTGS2, NOS3, TNF, and NOS2, with functional genetic variants, can exhibit different allelic, genotypic, and haplotypic frequencies in children with CZS [26]. A higher prevalence of the rs2297518 allele A in the NOS2 gene has also been observed in children with CZS. Significantly, the iNOS protein activity is somehow influenced by functional polymorphism NOS2 rs2297518. Enhanced protein activity and a higher level of nitric oxide (NO) are also presumably associated with A allele [27][28]. Neurogenesis and neurodevelopment have, in turn, been found to be substantially influenced by NO, whose dysregulation may impact the progression of various neurodevelopmental, neurobehavioral, and neurodegenerative disorders [29]. The rate of progression and development could be influenced by NO dysregulation linked to the individual response to ZIKV infection and by the patient’s genotype, even to the point of bringing about a congenital anomaly. Furthermore, CZS pathogenesis may be affected by single nucleotide variants: rs2076469 at the DISP3 gene and other rare variants in the IL12RB2 gene, due to their possible protective value and connection with neuronal proliferation and differentiation. Both phenotypes have been found altered in CZS patients, which may impact early immune-response to ZIKV infection [30][31][32]. Recent findings also reflect how two genes prominently involved in the regulation of bone development and cell–cell adhesion, FGFR3 and ITGB4, are upregulated in the brains of CZS patients [33].

    4. Reverse Genetics and Recombinant ZIKV

    The complex ways in which the pathology of ZIKV infection is affected by genetic traits will be instrumental in laying out therapeutic pathways and enhancing surveillance and prevention capabilities to counter the spread of ZIKV [34]. Reverse genetic strategies, either in vitro or in vivo, may constitute a valuable approach through which research will gain a more thorough understanding as to ZIKV’s biology and pathogenesis. The creation of recombinant viruses with specific mutations through the manipulation of the ZIKV genome has enabled researchers to shed a light on the function of viral proteins, the interactions involved between ZIKV and its host, and associated disease [35]. Research strategies harnessing reverse genetics have also proven valuable in the development of new effective prevention and control measures [36][37]. The bioengineering of replicating-competent recombinant ZIKV, which can be used to modify the ZIKV genomic RNA at the DNA level and express reporter genes, has, in fact, shown remarkable potential for the development of anti-viral therapeutic options to treat ZIKV infection [38][39], provided that the instability commonly linked to the construction of full-length cDNA clones can be overcome [40][41]. New research avenues are currently being pursued, relying on novel methods for more efficient and easier infectious clone construction, for instance, through the use of homologous recombination clones during plasmid construction [42].

    5. Prenatal Diagnosis

    The gold standard for prenatal diagnosis of ZIKV infection is the polymerase chain reaction essay (PCR) on amniotic fluid. Virus-specific IgM antibodies may be detected 3 days after the onset of symptoms. The serology findings can determine false positives due to cross-reaction with other flaviviruses (like West Nile virus, Dengue and yellow fever). After birth, the viral genome is detectable in saliva, breast milk, urine, and serum within several days after delivery; these data support the possible perinatal transmission of the infection [1].
    Another limitation for prenatal diagnosis of the infection is persistent viremia and viruria in pregnancy, even weeks and months after primary exposure [43]. In the case of microcephaly, defined head circumference <2SDS is detectable by ultrasound starting from the second trimester, whereas ZIKV infection occurs typically in the first trimester. Other ultrasound signs suggestive of infection include ventriculomegaly, brain calcifications and posterior fossa destructive lesions; these findings are not found in other congenital infections [44]. According to some studies, another typical sign is disproportion in fetal growth, such as an unusual femur sparing growth restriction [45].

    6. Clinical Signs

    The distinctive features of the congenital ZIKV syndrome in the new-born are the following: severe microcephaly with partially collapsed skull, redundant scalp skin, early closure of the fontanelles, macular scarring and focal pigmentary retinal mottling, congenital contractures of one or more joints (similar to arthrogryposis, very rare in other congenital infections) and extrapyramidal motor symptoms with marked hypertonia. According to some authors, microcephaly may develop in new-borns with a normal head circumference at birth [1][46]. In severe cases, placental insufficiency caused by infection can lead to fetal growth restriction and, sometimes, even to fetal demise [6][47].

    7. Neuroimaging

    Neuroimaging with computed tomography (CT) or magnetic resonance (MRI) has found calcifications of the cortico-medullary junction with band distribution, more frequently in the basal ganglia and less commonly in the thalamus. Other alterations include cysts, mainly in the occipital area, delayed myelination and ventriculomegaly (Table 1). The latter, if severe, may require ventricular-peritoneal shunt surgery. Some of the alterations mentioned above may be present even in children with normal head circumference [1].
    Table 1. MRI findings in congenital ZIKV infection.

    CT 1 and MRI 2 Findings in Congenital Zika Syndrome

    Punctate calcifications (basal ganglia > thalami)

    Severe ventriculomegaly

    Global delayed or hypo-myelination

    Pachygyria or polymicrogyria (mostly in the frontal lobes)

    Hypoplasia of the cerebellum and the brainstem.

    Enlarged cisterna magna

    Abnormalities of corpus callosum (hypoplasia/hypogenesis)

    Cysts/Pseudocysts (mainly in the occipital area)

    1 CT: computed tomography; 2 MRI: magnetic resonance.

    In congenital ZIKV infection, the whole development of the brain is compromised, with a reduction in cortical gyrification, cerebellar hypoplasia, and hypo/dysmyelination of the white matter in almost all affected subjects. These pathologic alterations are visible both with CT performed after birth and with fetal MRI [48].

    References

    1. De Vries, L.S. Viral Infections and the Neonatal Brain. Semin. Pediatr. Neurol. 2019, 32, 100769.
    2. Schirmer, D.A.; Kawwass, J.F. Epidemiology, Virology, and Pathogenesis of the Zika Virus: From Neglected Tropical Disease to a Focal Point of International Attention. Semin. Reprod. Med. 2016, 34, 261–265.
    3. Mehrjardi, M.Z. Is Zika Virus an Emerging TORCH Agent? An Invited Commentary. Virology 2017, 8, 1178122X17708993.
    4. Eloundou, S.N.; Sheffield, J.S. Prenatal Effects of Zika Virus and Management of the Pregnant Woman. Semin. Reprod. Med. 2016, 34, 280–284.
    5. Duttine, A.; Smythe, T.; Ribiero Calheiro de Sá, M.; Ferrite, S.; Zuurmond, M.; Moreira, M.E.; Collins, A.; Milner, K.; Kuper, H. Congenital Zika Syndrome—Assessing the Need for a Family Support Programme in Brazil. Int. J. Environ. Res. Public Health 2020, 17, 3559.
    6. Zuurmond, M.; Nyante, G.; Baltussen, M.; Seeley, J.; Abanga, J.; Shakespeare, T.; Collumbien, M.; Bernays, S. A Support Programme for Caregivers of Children with Disabilities in Ghana: Understanding the Impact on the Wellbeing of Caregivers. Child Care Health Dev. 2019, 45, 45–53.
    7. Kuper, H.; Lyra, T.M.; Moreira, M.E.L.; de Albuquerque, M.D.S.V.; de Araújo, T.V.B.; Fernandes, S.; Jofre-Bonet, M.; Larson, H.; Lopes de Melo, A.P.; Mendes, C.H.F.; et al. Social and Economic Impacts of Congenital Zika Syndrome in Brazil: Study Protocol and Rationale for a Mixed-Methods Study. Wellcome Open Res. 2019, 3, 127.
    8. Kuper, H.; Lopes Moreira, M.E.; Barreto de Araújo, T.V.; Valongueiro, S.; Fernandes, S.; Pinto, M.; Lyra, T.M. The Association of Depression, Anxiety, and Stress with Caring for a Child with Congenital Zika Syndrome in Brazil; Results of a Cross-Sectional Study. PLoS Negl. Trop. Dis. 2019, 13, e0007768.
    9. Dos Santos Costa, A.C.; Hasan, M.M.; Xenophontos, E.; Mohanan, P.; Bassey, E.E.; Hashim, H.T.; Ahmad, S.; Essar, M.Y. COVID-19 and Zika: An Emerging Dilemma for Brazil. J. Med. Virol. 2021, 93, 4124–4126.
    10. Pergolizzi, J.; LeQuang, J.A.; Umeda-Raffa, S.; Fleischer, C.; Pergolizzi, J.; Pergolizzi, C.; Raffa, R.B. The Zika Virus: Lurking behind the COVID-19 Pandemic? J. Clin. Pharm. Ther. 2021, 46, 267–276.
    11. Parasa, S.; Desai, M.; Thoguluva Chandrasekar, V.; Patel, H.K.; Kennedy, K.F.; Roesch, T.; Spadaccini, M.; Colombo, M.; Gabbiadini, R.; Artifon, E.L.A.; et al. Prevalence of Gastrointestinal Symptoms and Fecal Viral Shedding in Patients with Coronavirus Disease 2019: A Systematic Review and Meta-Analysis. JAMA Netw. Open 2020, 3, e2011335.
    12. Phadke, R.; Mohan, A.; Çavdaroğlu, S.; Dapke, K.; dos Santos Costa, A.C.; Riaz, M.M.A.; Hashim, H.T.; Essar, M.Y.; Ahmad, S. Dengue amidst COVID-19 in India: The Mystery of Plummeting Cases. J. Med. Virol. 2021, 93, 4120–4121.
    13. Pacheco, O.; Beltrán, M.; Nelson, C.A.; Valencia, D.; Tolosa, N.; Farr, S.L.; Padilla, A.V.; Tong, V.T.; Cuevas, E.L.; Espinosa-Bode, A.; et al. Zika Virus Disease in Colombia—Preliminary Report. N. Engl. J. Med. 2020, 383, e44.
    14. Coyne, C.B.; Lazear, H.M. Zika Virus—Reigniting the TORCH. Nat. Rev. Microbiol. 2016, 14, 707–715.
    15. Chen, Q.; Gouilly, J.; Ferrat, Y.J.; Espino, A.; Glaziou, Q.; Cartron, G.; El Costa, H.; Al-Daccak, R.; Jabrane-Ferrat, N. Metabolic Reprogramming by Zika Virus Provokes Inflammation in Human Placenta. Nat. Commun. 2020, 11, 2967.
    16. Weisblum, Y.; Oiknine-Djian, E.; Vorontsov, O.M.; Haimov-Kochman, R.; Zakay-Rones, Z.; Meir, K.; Shveiky, D.; Elgavish, S.; Nevo, Y.; Roseman, M.; et al. Zika Virus Infects Early- and Midgestation Human Maternal Decidual Tissues, Inducing Distinct Innate Tissue Responses in the Maternal-Fetal Interface. J. Virol. 2017, 91, e01905-16.
    17. Frenkel, L.D.; Gomez, F.; Sabahi, F. The Pathogenesis of Microcephaly Resulting from Congenital Infections: Why Is My Baby’s Head so Small? Eur. J. Clin. Microbiol. Infect. Dis. 2018, 37, 209–226.
    18. Zhou, K.; Wang, L.; Yu, D.; Huang, H.; Ji, H.; Mo, X. Molecular and Cellular Insights into Zika Virus-Related Neuropathies. J. Neurovirol. 2017, 23, 341–346.
    19. Nithiyanantham, S.F.; Badawi, A. Maternal Infection with Zika Virus and Prevalence of Congenital Disorders in Infants: Systematic Review and Meta-Analysis. Can. J. Public Health 2019, 110, 638–648.
    20. Gomes, J.A.; Sgarioni, E.; Boquett, J.A.; Terças-Trettel, A.C.P.; da Silva, J.H.; Ribeiro, B.F.R.; Galera, M.F.; de Oliveira, T.M.; Carvalho de Andrade, M.D.F.; Carvalho, I.F.; et al. Association between Genetic Variants in NOS2 and TNF Genes with Congenital Zika Syndrome and Severe Microcephaly. Viruses 2021, 13, 325.
    21. Li, G.; Poulsen, M.; Fenyvuesvolgyi, C.; Yashiroda, Y.; Yoshida, M.; Simard, J.M.; Gallo, R.C.; Zhao, R.Y. Characterization of Cytopathic Factors through Genome-Wide Analysis of the Zika Viral Proteins in Fission Yeast. Proc. Natl. Acad. Sci. USA 2017, 114, E376–E385.
    22. Zhang, J.-W.; Wang, H.; Liu, J.; Ma, L.; Hua, R.-H.; Bu, Z.-G. Generation of A Stable GFP-Reporter Zika Virus System for High-Throughput Screening of Zika Virus Inhibitors. Virol. Sin. 2021, 36, 476–489.
    23. Li, Y.; Muffat, J.; Omer Javed, A.; Keys, H.R.; Lungjangwa, T.; Bosch, I.; Khan, M.; Virgilio, M.C.; Gehrke, L.; Sabatini, D.M.; et al. Genome-Wide CRISPR Screen for Zika Virus Resistance in Human Neural Cells. Proc. Natl. Acad. Sci. USA 2019, 116, 9527–9532.
    24. Piergentili, R.; Del Rio, A.; Signore, F.; Umani Ronchi, F.; Marinelli, E.; Zaami, S. CRISPR-Cas and Its Wide-Ranging Applications: From Human Genome Editing to Environmental Implications, Technical Limitations, Hazards and Bioethical Issues. Cells 2021, 10, 969.
    25. Ferraris, P.; Wichit, S.; Cordel, N.; Missé, D. Human Host Genetics and Susceptibility to ZIKV Infection. Infect. Genet. Evol. 2021, 95, 105066.
    26. Borda, V.; da Silva Francisco Junior, R.; Carvalho, J.B.; Morais, G.L.; Duque Rossi, Á.; Pezzuto, P.; Azevedo, G.S.; Schamber-Reis, B.L.; Portari, E.A.; Melo, A.; et al. Whole-Exome Sequencing Reveals Insights into Genetic Susceptibility to Congenital Zika Syndrome. PLoS Negl. Trop. Dis. 2021, 15, e0009507.
    27. Garry, P.S.; Ezra, M.; Rowland, M.J.; Westbrook, J.; Pattinson, K.T.S. The Role of the Nitric Oxide Pathway in Brain Injury and Its Treatment—From Bench to Bedside. Exp. Neurol. 2015, 263, 235–243.
    28. Dhillon, S.S.; Mastropaolo, L.A.; Murchie, R.; Griffiths, C.; Thöni, C.; Elkadri, A.; Xu, W.; Mack, A.; Walters, T.; Guo, C.; et al. Higher Activity of the Inducible Nitric Oxide Synthase Contributes to Very Early Onset Inflammatory Bowel Disease. Clin. Transl. Gastroenterol. 2014, 5, e46.
    29. Tripathi, M.K.; Kartawy, M.; Amal, H. The Role of Nitric Oxide in Brain Disorders: Autism Spectrum Disorder and Other Psychiatric, Neurological, and Neurodegenerative Disorders. Redox Biol. 2020, 34, 101567.
    30. Hung, S.-J.; Huang, S.-W. Contributions of Genetic Evolution to Zika Virus Emergence. Front. Microbiol. 2021, 12, 655065.
    31. Carbaugh, D.L.; Zhou, S.; Sanders, W.; Moorman, N.J.; Swanstrom, R.; Lazear, H.M. Two Genetic Differences between Closely Related Zika Virus Strains Determine Pathogenic Outcome in Mice. J. Virol. 2020, 94, e00618-20.
    32. Haddow, A.D.; Schuh, A.J.; Yasuda, C.Y.; Kasper, M.R.; Heang, V.; Huy, R.; Guzman, H.; Tesh, R.B.; Weaver, S.C. Genetic Characterization of Zika Virus Strains: Geographic Expansion of the Asian Lineage. PLoS Negl. Trop. Dis. 2012, 6, e1477.
    33. Aguiar, R.S.; Pohl, F.; Morais, G.L.; Nogueira, F.C.S.; Carvalho, J.B.; Guida, L.; Arge, L.W.P.; Melo, A.; Moreira, M.E.L.; Cunha, D.P.; et al. Molecular Alterations in the Extracellular Matrix in the Brains of Newborns with Congenital Zika Syndrome. Sci. Signal. 2020, 13, eaay6736.
    34. Strottmann, D.M.; Zanluca, C.; Mosimann, A.L.P.; Koishi, A.C.; Auwerter, N.C.; Faoro, H.; Cataneo, A.H.D.; Kuczera, D.; Wowk, P.F.; Bordignon, J.; et al. Genetic and Biological Characterisation of Zika Virus Isolates from Different Brazilian Regions. Mem. Inst. Oswaldo Cruz 2019, 114, e190150.
    35. Liu, Y.; Liu, J.; Du, S.; Shan, C.; Nie, K.; Zhang, R.; Li, X.-F.; Zhang, R.; Wang, T.; Qin, C.-F.; et al. Evolutionary Enhancement of Zika Virus Infectivity in Aedes Aegypti Mosquitoes. Nature 2017, 545, 482–486.
    36. Yang, Y.; Shan, C.; Zou, J.; Muruato, A.E.; Bruno, D.N.; de Almeida Medeiros Daniele, B.; Vasconcelos, P.F.C.; Rossi, S.L.; Weaver, S.C.; Xie, X.; et al. A CDNA Clone-Launched Platform for High-Yield Production of Inactivated Zika Vaccine. EBioMedicine 2017, 17, 145–156.
    37. Lu, C.-Y.; Lin, C.-S.; Lai, H.-C.; Yu, Y.-W.; Liao, C.-Y.; Su, W.-C.; Ko, B.-H.; Chang, Y.-S.; Huang, S.-H.; Lin, C.-W. The Rescue and Characterization of Recombinant, Microcephaly-Associated Zika Viruses as Single-Round Infectious Particles. Viruses 2019, 11, 1005.
    38. Kümmerer, B.M. Establishment and Application of Flavivirus Replicons. Adv. Exp. Med. Biol. 2018, 1062, 165–173.
    39. Komoto, S.; Fukuda, S.; Murata, T.; Taniguchi, K. Human Rotavirus Reverse Genetics Systems to Study Viral Replication and Pathogenesis. Viruses 2021, 13, 1791.
    40. Gao, J.; Chen, J.; Lu, W.; Cai, J.; Shi, L.; Zhao, W.; Zhang, B. Construction of an Infectious Clone of Zika Virus Stably Expressing an EGFP Marker in a Eukaryotic Expression System. Virol. J. 2021, 18, 151.
    41. Ávila-Pérez, G.; Nogales, A.; Martín, V.; Almazán, F.; Martínez-Sobrido, L. Reverse Genetic Approaches for the Generation of Recombinant Zika Virus. Viruses 2018, 10, 597.
    42. Qin, Z.; Chen, Y.; Yu, J.; He, X.; Liu, X.; Zhu, L.; Wu, Q.; Wan, C.; Zhang, B.; Zhao, W. Rapid Construction of an Infectious Clone of the Zika Virus, Strain ZKC2. Front. Microbiol. 2021, 12, 752578.
    43. Eppes, C.; Rac, M.; Dunn, J.; Versalovic, J.; Murray, K.O.; Suter, M.A.; Sanz Cortes, M.; Espinoza, J.; Seferovic, M.D.; Lee, W.; et al. Testing for Zika Virus Infection in Pregnancy: Key Concepts to Deal with an Emerging Epidemic. Am. J. Obstet. Gynecol. 2017, 216, 209–225.
    44. Sarno, M.; Aquino, M.; Pimentel, K.; Cabral, R.; Costa, G.; Bastos, F.; Brites, C. Progressive Lesions of Central Nervous System in Microcephalic Fetuses with Suspected Congenital Zika Virus Syndrome. Ultrasound Obstet. Gynecol. 2017, 50, 717–722.
    45. Walker, C.L.; Little, M.-T.E.; Roby, J.A.; Armistead, B.; Gale, M.; Rajagopal, L.; Nelson, B.R.; Ehinger, N.; Mason, B.; Nayeri, U.; et al. Zika Virus and the Nonmicrocephalic Fetus: Why We Should Still Worry. Am. J. Obstet. Gynecol. 2019, 220, 45–56.
    46. Rasmussen, S.A.; Meaney-Delman, D.M.; Petersen, L.R.; Jamieson, D.J. Studying the Effects of Emerging Infections on the Fetus: Experience with West Nile and Zika Viruses. Birth Defects Res. 2017, 109, 363–371.
    47. Freitas, D.A.; Souza-Santos, R.; Carvalho, L.M.A.; Barros, W.B.; Neves, L.M.; Brasil, P.; Wakimoto, M.D. Congenital Zika Syndrome: A Systematic Review. PLoS ONE 2020, 15, e0242367.
    48. Araujo Júnior, E.; Carvalho, F.H.C.; Tonni, G.; Werner, H. Prenatal Imaging Findings in Fetal Zika Virus Infection. Curr. Opin. Obstet. Gynecol. 2017, 29, 95–105.
    More
    Information
    Subjects: Allergy
    Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
    View Times: 104
    Revisions: 2 times (View History)
    Update Date: 21 Mar 2022
    Table of Contents
      1000/1000

      Confirm

      Are you sure you want to delete?

      Video Upload Options

      Do you have a full video?
      Cite
      If you have any further questions, please contact Encyclopedia Editorial Office.
      Gullo, G. Congenital Zika Syndrome. Encyclopedia. Available online: https://encyclopedia.pub/entry/20701 (accessed on 07 February 2023).
      Gullo G. Congenital Zika Syndrome. Encyclopedia. Available at: https://encyclopedia.pub/entry/20701. Accessed February 07, 2023.
      Gullo, Giuseppe. "Congenital Zika Syndrome," Encyclopedia, https://encyclopedia.pub/entry/20701 (accessed February 07, 2023).
      Gullo, G. (2022, March 17). Congenital Zika Syndrome. In Encyclopedia. https://encyclopedia.pub/entry/20701
      Gullo, Giuseppe. ''Congenital Zika Syndrome.'' Encyclopedia. Web. 17 March, 2022.
      Top
      Feedback